Critical Illness Polyneuropathy Developing In The Early Period After An Epileptic Seizure: Two Case Reports

Öz

Critical illness polyneuropathy (CIP) is characterized by muscle weakness and atrophy in intensive care patients. Although recovery may occur by addressing the underlying cause, plasmapheresis or immunoglobulin therapy may be necessary in severe cases. We present two female patients (aged 76 and 52) who developed CIP in the early phase following epileptic seizures. CIP was suspected due to difficulty in ventilator weaning, and EMG confirmed the diagnosis. Both patients underwent five sessions of plasmapheresis and were successfully weaned from the ventilator, regaining full (5/5) muscle strength in all extremities. Early diagnosis is crucial in preventing complications and increasing treatment success in CIP.

Anahtar Kelimeler

• Critical illness polyneuropathy
• nonconvulsive status epilepticus
• mechanical ventilator

Epileptik Nöbet Sonrası Erken Dönemde Gelişen Kritik Hastalık Polinöropatisi: İki Olgu Sunumu

Öz

Kritik hastalık polinöropatisi (CIP), yoğun bakım hastalarında kas güçsüzlüğü ve atrofi ile karakterizedir. Altta yatan nedenin tedavisiyle iyileşme mümkün olsa da, ağır vakalarda plazmaferez veya immünoglobulin tedavisi gerekebilir. Bu yazıda epileptik nöbetlerin ardından erken dönemde CIP gelişen iki kadın hasta (76 ve 52 yaşlarında) sunulmaktadır. Her iki olguda da ventilatörden ayırma güçlüğü nedeniyle CIP şüphesi oluşmuş ve EMG ile tanı doğrulanmıştır. Her iki hastaya da beşer seans plazmaferez uygulanmış ve başarıyla ventilatörden ayrılmışlardır. Tüm ekstremitelerde kas gücü tamamen (5/5) geri kazanılmıştır. CIP'te erken tanı, komplikasyonların önlenmesi ve tedavi başarısının artırılması açısından kritik öneme sahiptir.

Anahtar Kelimeler

• Kritik hastalık polinöropatisi
• konvülsif olmayan status epileptikus
• mekanik ventilatör

Kaynakça

1. Kerbaul F, Brousse M, Collart F, et al. Combination of histopathological and electromyographic patterns can help to evaluate functional outcome of critical ill patients with neuromuscular weakness syndromes. Crit Care. 2004;8(6):R358-66. doi:10.1186/cc2925
2. Hermans G, De Jonghe B, Bruyninckx F, et al.. Clinical review: Critical illness polyneuropathy and myopathy. Crit Care. 2008;12(6):238. doi:10.1186/cc7100
3. Mohr M, Englisch L, Roth A, et al. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med. 1997;23(11):1144-1149. doi:10.1007/s001340050471
4. Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve. 2005;32(2):140-163. doi:10.1002/mus.20304
5. Hantus S. Epilepsy Emergencies. Continuum (Minneap Minn). 2016;22 (1 Epilepsy): 173-190. doi: 10.1212/CON. 0000000000000285
6. van Mook WNKA, Hulsewé-Evers RPMG. Critical illness polyneuropathy. Curr Opin Crit Care. 2002;8(4):302-310. doi:10.1097/00075198-200208000-00006
7. Garnacho-Montero J, Madrazo-Osuna J, García-Garmendia JL, et al. Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med. 2001;27(8):1288-1296. doi:10.1007/s001340101009
8. Wijdicks EF, Litchy WJ, Harrison BA, et al. The clinical spectrum of critical illness polyneuropathy. Mayo Clin Proc. 1994;69(10):955-959. doi:10.1016/s0025-6196(12)61819-9

9. Shepherd S, Batra A, Lerner DP. Review of Critical Illness Myopathy and Neuropathy. The Neurohospitalist. 2017;7(1):41-48. doi:10.1177/1941874416663279
10. Johnson KL. Neuromuscular complications in the intensive care unit: critical illness polyneuromyopathy. AACN Adv Crit Care. 2007;18(2):162-167. doi:10.1097/01. AACN.0000269260.99169.70
11. Abdulla E, Janjua T, Agrawal A et al. Neurogenically Originated Inflammatory Response Syndrome: Role in the Neurocritical Patient. J Neurointensive Care. 2022;5(2):39-43. doi:10.32587/jnic.2022.00514
12. Rony RMIK, Shokrani A, Malhi NK, et al. Therapeutic Plasma Exchange: Current and Emerging Applications to Mitigate Cellular Signaling in Disease. Biomolecules. 2025;15(7):1000. Published 2025 Jul 12. doi:10.3390/biom15071000